



Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
 (Use several sheets if necessary)

 ATTY DOCKET NO.  
 6750-157-999  
 (CAM No. 305158-999155)

 APPLICATION NO.  
 10/669,823

 APPLICANT:  
 Qun SUN et al.

 FILING DATE:  
 September 23, 2003

 ART UNIT: 1624  
 CONF. NO.: 6999

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01				
	A02				
	A03				
	A04				
	A05				

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01						
	B02						
	B03						
	B04						
	B05						

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.
W	C32	SZALLASI et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," <i>Molec. Pharmacol.</i> 56:581-587 (1999)
W	C33	LOPEZ-RODRIGUEZ et al., "VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain," <i>Mini-Reviews in Medicinal Chem.</i> 3(7):729-48 (2003)
W	C34	POMONIS et al., "N-(4-Tertiarybutylphenyl)-4-(3-chlorophenyl)-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain," <i>J. Pharmacol. Exper. Therapeutics</i> 306(1):387-393 (2003)
W	C35	WRIGGLESWORTH et al., "Capsaicin-like Agonists," <i>Drugs of the Future</i> , 23(5):531-38 (1998)
W	C36	SZALLASI et al., "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacol. Revs.</i> , 51(2):159-211 (1999)
W	C37	BEVAN et al., "Vanilloid Receptors: Pivotal Molecules in Nociception," <i>Current Opinions in CPNS Investigational Drugs</i> , 2(2):178-85 (2000)
W	C38	WANG et al., "High Affinity Antagonists of the Vanilloid Receptor," <i>Mol. Pharmacol.</i> 62(4):947-56 (2002)

EXAMINER

V. Balasubramanian

DATE CONSIDERED

4/14/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.